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Transcriptional Targeting of Replication-defective Adenovirus Transgene 


























Gene transfer using replication-defective adenoviruses
(RDAd) holds promise for the treatment of vascular prolif-
erative disorders, but is potentially limited by the capacity
of these viruses to infect multiple cell lineages. We have
generated an RDAd vector, designated AdSM22-lacZ, which




 reporter gene under the tran-





 promoter. Here, we show that in vitro AdSM22-lacZ




 reporter gene in primary
rat aortic SMCs and immortalized A7r5 SMCs, but not in
primary human umbilical vein endothelial cells (HUVECs)
or NIH 3T3 cells. Consistent with these results, after in-
traarterial administration of AdSM22-lacZ to control and





was detected within SMCs of the tunica media and neoin-
tima, but not within endothelial or adventitial cells. More-





 gene expression in the liver or lungs. Finally,
we have shown that direct injection of AdSM22-lacZ into
SMC-containing tissues such as the ureter and bladder re-
sults in high-level transgene expression in visceral SMCs.
Taken together, these results demonstrate that transgene
expression after infection with an RDAd vector can be regu-
lated in an SMC lineage–restricted fashion by using a tran-




promoter. The demonstration of an efficient gene delivery
system targeted specifically to SMCs provides a novel
means to restrict expression of recombinant gene products






























and modulate their phenotype has been implicated in the
pathogenesis of a number of diseases including atherosclerosis,
restenosis after percutaneous transluminal coronary angio-
plasty, and asthma (for reviews see references 1–4). Gene
transfer into SMCs holds promise both for elucidating the
pathogenesis of these diseases and for their treatment (5–12).
Replication-defective adenovirus vectors (RDAd) are particu-
larly well suited for facilitating efficient gene transfer into
SMCs in vivo. These viruses can be prepared at high titers and
have been shown to efficiently infect SMCs both in vitro and in
vivo (13, 14). In addition, RDAd display a relatively favorable
safety profile. They do not integrate into the host genome and
have not been associated with persistent infections or malig-
nancies in humans (for review see reference 15). Several investi-
gators have taken advantage of these properties to demonstrate
that catheter-mediated delivery of RDAd encoding both cyto-
toxic and cytostatic proteins can be used to decrease SMC pro-
liferation and neointima formation in both small and large ani-
mal models of vascular injury and restenosis (5–7, 12, 16, 17).
Although RDAd efficiently transduce both resting and
proliferating SMCs in vivo, a potential limitation of their use in
the clinical setting is their capacity to infect and program trans-
gene expression in many different cell lineages and tissues (5,
15). For example, localized arterial administration of RDAd
results in efficient infection of endothelial cells, vascular
SMCs, and adventitial cells (13, 14). Moreover, intravenous
administration of these vectors results in high-level gene trans-
fer to the liver and lung (18–20). Several approaches have been
used in an attempt to circumvent this problem. First, it has
been possible to restrict the expression of a viral transgene to a
specific cell or tissue by administering the virus ex vivo. How-
ever, this approach is laborious and is not practical for the
treatment of most vascular proliferative disorders. A second
approach has involved delivery of adenoviral particles locally
within the vasculature (to the site of vessel wall injury) or
within a tissue (5–7, 21). Specially modified catheter delivery
systems including coated balloons and intravascular stents
have been designed in order to achieve high local concentra-
tions of adenovirus within the vasculature (22–24). However,
the usefulness of these approaches may be limited within the
human coronary circulation due to the high frequency of side
branches. Moreover, such catheter delivery systems do not re-
strict transgene expression to specific cell types in the vessel
wall. Finally, several groups have reported that the tissue tro-
pism of RDAd can be modified by electrostatically conjugat-
ing adenoviral proteins to ligands that can bind specifically to
tissue-specific cell surface receptors (25, 26). This approach
has been used to successfully target RDAd to hepatocytes and
hematopoietic progenitor cell lines (26).
The use of tissue-specific transcriptional regulatory ele-
ments represents an alternative strategy to restrict adenoviral
transgene expression to specific cell lineages or tissues in vivo
(20). While theoretically appealing, this strategy is potentially
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limited because the adenovirus genome contains multiple
highly active transcriptional enhancers that are capable of
transactivating a variety of different promoters in multiple cell
lineages (15). Such a targeting strategy is particularly problem-
atic in SMCs because of the lack of SMC-specific transcrip-
tional regulatory elements that function in vivo. This is due
primarily to the lack of definitive markers of this muscle cell
lineage and the poorly understood and diverse embryological





 is an early marker of the SMC lineage that is ex-
pressed at high levels exclusively in visceral and vascular SMCs





 promoter activates transcription exclusively
in arterial SMCs during postnatal development in transgenic




promoter could be used to restrict the activity of an RDAd to





 reporter gene under the transcriptional control




 promoter. In the studies de-





 reporter gene encoded by AdSM22-lacZ is ex-
pressed exclusively in SMCs. Moreover, the SMC specificity of
the AdSM22-lacZ virus is maintained after intraarterial ad-
ministration of the virus to an isolated segment of both unin-
jured and balloon-injured rat carotid arteries. In contrast to
previously described adenoviral vectors (18–20), intravenous
administration of AdSM22-lacZ does not produce detectable
transgene expression in the liver or lung. Finally, we have dem-





visceral as well as vascular SMCs in vivo. These studies dem-
onstrate that RDAd-encoded transgene expression can be





demonstration of an efficient gene delivery system targeted
specifically to SMCs provides a novel means to deliver recom-





 promoter-driven RDAd may prove useful in the





Plasmids and replication-defective adenoviral vectors.
 
The pAdSM22














plasmid (32). The pAdSM22-lacZ plasmid was generated by subclon-













gene into the HindIII/BamHI-digested pAdSM22 plasmid. The










the human 4F2 heavy chain transcriptional enhancer (33) was gener-
ated by recombination in 293 cells between the pAdSM22-lacZ plas-
mid DNA and E1- and E3-deleted Ad5Sub360 genomic DNA di-
gested with XbaI and ClaI as described previously (34). The structure
of this virus was confirmed by Southern blot analyses. The AdCMV-




 reporter gene under the tran-
scriptional control of the cytomegalovirus (CMV) immediate early
gene promoter/enhancer has been described previously (35). Recom-
binant viruses were plaque purified three times to avoid contamina-
tion with replication-competent virus. High titer adenoviral stocks
were prepared by infecting 293 cells with 2–5 plaque-forming units
(PFU) of virus per cell as described previously (34). Titers of each ce-
sium chloride purified viral stock were determined from the absor-








 PFU/ml) and were con-
firmed by plaque assay as described previously (34).
 
Cell culture and in vitro infection with RDAd.
 
Primary rat aortic
SMCs were isolated from 12–16-wk-old Sprague-Dawley rats and





-actin when isolated using this technique (30). In
all experiments, only third passage primary rat aortic SMCs were
used. Immortalized rat vascular A7r5 SMCs, passage 4 human umbil-
ical vein endothelial cells (HUVECs), and mouse NIH 3T3 fibro-
blasts were grown as described previously (31). Cells were placed in
medium containing 2% FBS and infected with either 1, 10, or 100
PFU/cell of purified adenoviral stocks. After infection, cells were
washed in PBS and placed in growth medium containing 10% FBS. 72 h
after infection, cells were harvested for preparation of DNA and














from 10 representative high-power fields were counted in each sec-








 cells was calculated. The data are









ments involving animals were approved by the University of Chicago
Committee on Animal Care and Use. The Sprague-Dawley rats were
housed and cared for according to National Institutes of Health
guidelines in the A.J. Carlson Animal Research Facility at the Uni-
versity of Chicago.
 
Northern and Southern blot analyses.
 
Southern and Northern blot
analyses were performed as described previously (37). PCR-gener-









 plasmid; Clontech, Palo Alto, CA) was radiolabeled
and used for the Southern and Northern blot analyses. Quantitative
image analyses were performed using a PhosphorImager (Molecular
Dynamics, Sunnyvale, CA).
 
Intraarterial administration of RDAd in uninjured and balloon-
injured rat carotid arteries.
 
After induction of anesthesia and intuba-
tion, the left and right carotid arteries of adult Sprague-Dawley rats
were isolated and a balloon injury was created by dilatation with a 2F
Fogarty catheter as described previously (6). A 24-gauge intravenous
catheter was introduced into the lumen of uninjured or balloon-








 PFU of AdSM22-lacZ or AdCMV-
lacZ was instilled into the isolated arterial segment for 5 min. 7 d after
infection, rats were killed and the isolated segments of carotid artery





tosidase activity with X-gal as described previously (36). Photo-
microscopy was performed using Kodak EPT 160 film and a Zeiss
Axiophot microscope.
 
Intravenous administration of RDAd.
 
12–16-wk-old Sprague-Daw-








 PFU of AdSM22-
lacZ or AdCMV-lacZ, respectively. Liver function tests were per-
formed on serum samples obtained 7 d after infection using Kodak
DT60II and DTSCII automated analyzers. To determine the signifi-
cance of alterations in liver function tests observed between control,




tests were performed. 7 d after injection, rats were killed and the in-
jected tissue, as well as the liver, lung, kidney, and carotid arteries





with X-gal as described previously (36).
 
Direct injection of RDAd into visceral SMCs and skeletal muscle.
 
Direct injection of AdSM22-lacZ into SMC-containing tissues and
skeletal muscle was performed after induction of anesthesia and intu-




 PFU of the AdSM22-lacZ virus was in-
jected directly with a 30-gauge needle into the wall of the ureter, the
bladder wall, or intramuscularly. The site of each injection was
marked by a suture. 7 d after injection, the sites of injection were iso-








Transgene expression from AdSM22-lacZ is restricted to SMCs
in vitro.
 




 promoter has been shown











moter could be used to restrict the expression of a recombi-
nant gene product encoded by an RDAd to SMCs, we con-

















). In the experiments de-
scribed below, the activity of AdSM22-lacZ was compared





 reporter gene is under the transcriptional con-
trol of the ubiquitously active CMV immediate early gene pro-









To assess the activity of AdSM22-lacZ in cells transduced
in vitro, replicate cultures of primary rat aortic SMCs were in-
fected with 1, 10, and 100 PFU/cell of either AdSM22-lacZ or





-galactosidase activity (as assessed by blue














after infection with 1, 10, and 100 PFU/cell, respectively, of





was comparable to that observed after infection of replicate









). Consistent with these findings, 10, 70, and 90%, respec-




 transgene after infection with 1, 10, and 100 PFU/cell of




 and data not shown). This efficiency of
transgene expression was, again, comparable to that observed
after infection of this immortalized SMC line with the AdCMV-




 and data not shown).




 promoter restricted ex-




 reporter gene to SMCs, primary HUVECs
and NIH 3T3 fibroblasts were infected with AdSM22-lacZ or
the AdCMV-lacZ control virus. In contrast to the high effi-
ciency of transgene expression observed after AdSM22-lacZ–
















-galactosidase activity was not detect-
able in HUVECs or NIH 3T3 cells after infection with












). In contrast, 10,





-galactosidase activity after infection with 1, 10, and 100

















-galactosidase activity after infection with 100 PFU/





Southern blot analyses of DNA harvested from HUVECs
infected 72 h previously with AdSM22-lacZ demonstrated the





















). The hybridization signal was comparable in in-
tensity to that obtained with DNA harvested from HUVECs
infected with the AdCMV-lacZ control virus, thereby confirm-
















). Of note, the different sizes of the lacZ





consistent with the expected patterns of restriction endonu-
clease digestion of each adenoviral vector with BglII. Despite
the fact that AdSM22-lacZ and AdCMV-lacZ both efficiently




 transgene mRNA was detected in
the AdSM22-lacZ infected HUVECs by Northern blot analy-












). In contrast, HUVECs infected




















). Taken together, these
data demonstrated that AdSM22-lacZ programs SMC-specific
transgene expression in vitro and confirmed that the lineage-
restricted expression of the transgene was regulated at a tran-




ntraarterial administration of the AdSM22-lacZ virus to







 promoter could be used to restrict ade-









 PFU of either AdSM22-lacZ or the control AdCMV-
lacZ virus was introduced into isolated segments of uninjured








, diffuse blue staining of the vascular endothelium was
Figure 1. Structure and in vitro expression of AdSM22-lacZ. (A) 
Schematic representations of the AdSM22-lacZ and AdCMV-lacZ 
adenoviral vectors. The AdSM22-lacZ vector (top) encodes the bac-
terial lacZ reporter gene (black box) and bovine growth hormone 
polyadenylation signal (box with horizontal lines) under the tran-
scriptional control of the 441-bp murine SM22a promoter (box with 
diagonal lines) and the 450-bp human 4F2 transcriptional enhancer 
(white box). The E1 and E3 regions of the Ad5Sub360 adenoviral ge-
nome were deleted (DE3), rendering the virus replication-defective. 
The AdCMV-lacZ control virus encodes the lacZ reporter gene 
(black box) under the transcriptional control of the CMV immediate 
early gene promoter enhancer (box filled with dots). (B) Comparison 
of the activity of AdSM22-lacZ and the AdCMV-lacZ control virus in 
primary cultures of rat aortic smooth muscle cells (VSMC) and 
HUVECs. Primary cultures of VSMCs or HUVECs were infected 
with 1, 10, and 100 PFU of either AdSM22-lacZ (black squares and 
black circles) or AdCMV-lacZ (open squares and open circles) and 
the percentage of cells expressing b-galactosidase activity was quanti-
tated 72 h after infection. Data are expressed as the mean percentage 
of cells expressing bgal activity6SEM.
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Figure 2. SMC specificity of AdSM22-lacZ after in vitro gene transduction. Replicate cultures of primary rat aortic SMCs (A and B), A7r5 
SMCs (C and D), HUVECs (E and F), and NIH 3T3 fibroblasts (G and H) were infected with 10 PFU/cell of either the AdSM22-lacZ virus (A, 
C, E, and G), or the AdCMV-lacZ control virus (B, D, F, and H). 72 h after infection, cells were fixed and stained for b-galactosidase activity as 
described in Methods. Expression of the lacZ reporter gene encoded within the AdSM22-lacZ virus was observed in primary rat aortic SMCs 
(A) and the immortalized SMC line A7r5 (C), but not in HUVECs (E) or NIH 3T3 cells (G). In contrast, the lacZ reporter gene encoded within 
the AdCMV-lacZ control virus was expressed in both SMCs and non-SMCs.
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tery for 5 min immediately after balloon injury (Fig. 4, E and
F). 7 d after infection, the injured arterial segments were iso-
lated and the pattern of b-galactosidase expression was com-
pared with that observed in the uninfected balloon-injured
contra lateral artery. In contrast to the low level b-galactosi-
dase activity observed in the uninjured carotid artery infected
with the AdSM22-lacZ virus, higher efficiency gene transfer
was achieved in these balloon-injured arterial segments (com-
pare Fig. 4, C and E). The majority of the SMCs expressing
b-galactosidase activity were located within the tunica media
(Fig. 4 F, black arrowheads). In addition, rare cells within the
neointima also stained light blue (Fig. 4 F, open arrowhead).
Consistent with previous reports, gene transfer was preferen-
tially observed in the SMCs underlying the site of neointimal
proliferation (Fig. 4 E). Finally, it is noteworthy that lacZ
transgene expression was not observed in endothelial cells at
the margins of the vessel wall injury, where endothelial cells
remained intact (data not shown). Taken together, these data
demonstrated that the AdSM22-lacZ virus maintains its SMC-
specific pattern of transgene expression after intraarterial ad-
ministration and that it can be used to efficiently transduce ar-
terial SMCs in the balloon-injured rat carotid artery.
Expression of the lacZ reporter gene after intravenous injec-
tion of AdSM22-lacZ. Intravenous administration of RDAd
results in high level gene transfer to the liver and lung, thereby
potentially limiting the utility of these viruses in some clinical
settings (18–20). To determine whether the SMC-specific pat-
tern of expression of the lacZ reporter gene expression pro-
grammed by the AdSM22-lacZ virus would be maintained
after intravenous administration, 1010 PFU of either AdSM22-
lacZ or the control AdCMV-lacZ virus was injected intrave-
nously into adult Sprague-Dawley rats and representative sec-
tions from the livers and lungs of these rats (as well as other
tissues) were stained for b-galactosidase activity. lacZ expres-
sion was observed throughout the livers of rats infected with
the AdCMV-lacZ control virus (Fig. 5 E). In addition, focal
patches of b-gal1 cells were observed within perivascular re-
gions of the lung of AdCMV-lacZ–infected rats (Fig. 5 F). In
contrast, 7 d after infection with AdSM22-lacZ, histological
sections of both the liver and lung (Fig. 5, C and D) were indis-
tinguishable from those obtained from uninfected control rats
(Fig. 5, A and B). These data suggest that in contrast to RDAd
containing virally driven and/or ubiquitously active transcrip-
tional regulatory elements, AdSM22-lacZ restricts transgene
expression to SMCs after intravenous administration.
To determine whether intravenous administration of
AdSM22-lacZ caused abnormalities in liver function despite
the finding that the lacZ reporter gene encoded by this virus
was not expressed in this tissue (see Fig. 5 C), adult Sprague-
Dawley rats were injected intravenously with 1010 PFU of the
AdSM22-lacZ virus and liver function tests were performed on
serum samples obtained 7 d after infection. No statistically sig-
nificant elevations in serum alkaline phosphatase (AP), ala-
nine aminotransferase (ALT), aspartate aminotransferase
(AST), g-glutamyltranspeptidase, total bilirubin, total protein,
and albumin were observed in rats infected with the AdSM22-
lacZ virus (Table I) (P . 0.05). However, small, but consistent,
elevations in the mean serum concentrations of ALT, AST,
and AP were observed (Table I). In contrast, statistically sig-
nificant elevations in ALT and AST serum concentrations
were observed 7 d after intravenous administration of 1010
PFU of the AdCMV-lacZ control virus (P , 0.05). In addition,
Figure 3. Expression of 
the lacZ transgene en-
coded by AdSM22-
lacZ is regulated at a 
transcriptional or post-
transcriptional level. 
(A) Southern blot anal-
yses of AdSM22-lacZ 
and AdCMV-lacZ–
infected HUVECs. 
High molecular weight 
DNA prepared from 
HUVECs infected with 
10 and 100 PFU/cell 
(MOI), respectively, of 
either AdSM22-lacZ or 
AdCMV-lacZ was di-
gested with BglII and 
hybridized to the radio-
labeled lacZ cDNA 
probe under high strin-
gency conditions. The 
hybridization signals 
are indicated with ar-
rows to the right of the 
gel. Size markers in ki-
lobases are shown to 
the left of the blot. (B) 
Northern blot analyses 
of AdSM22-lacZ and 
AdCMV-lacZ–infected 
HUVECs. The top 
panel shows a Northern 
blot performed with 
RNA prepared from 
HUVECs infected 72 h 
previously with 10 and 
100 PFU/cell (MOI), 
respectively, of either 
AdCMV-lacZ or 
AdSM22-lacZ and the 
radiolabeled lacZ cDNA 
probe. The hybridiza-
tion signal demonstrated in cells infected with AdCMV-lacZ is indi-
cated with an arrow to the right of the blot. Size markers in kilobases 
are shown to the left of the blot. The bottom panel shows the ethid-
ium bromide–stained gel before membrane transfer. The position of 
the 28S ribosomal RNA band is indicated.
observed 7 d after administration of the control AdCMV-lacZ
virus into the uninjured rat carotid artery (Fig. 4 B, arrow-
heads). In addition, rare cells within the adventitia also stained
blue (Fig. 4 A). In contrast, when AdSM22-lacZ was intro-
duced into the uninjured rat carotid artery, b-galactosidase ac-
tivity was not observed within either endothelial or adventitial
cells (Fig. 4 C). However, rare lacZ-expressing SMCs were ob-
served in the superficial (abluminal) layer of the tunica media
(Fig. 4 D, arrowhead). These data suggested that the SMC
specificity of AdSM22-lacZ transgene expression is main-
tained after intraarterial administration of AdSM22-lacZ into
an isolated segment of the uninjured rat carotid artery.
To determine the cell specificity of transgene expression in
balloon-injured rat carotid arteries, 2 3 109 PFU of AdSM22-
lacZ was instilled into an isolated segment of the rat carotid ar-
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Figure 4. lacZ transgene expression in uninjured and balloon-injured rat carotid arteries infected with AdSM22-lacZ and AdCMV-lacZ. (A–D) 
Isolated segments of uninjured rat carotid arteries were infected with 109 PFU of either AdSM22-lacZ or the control AdCMV-lacZ virus. 7 d af-
ter infection, rats were killed, and the carotid arteries were removed and stained for b-galactosidase activity. (A and B) In uninjured arteries in-
fected with AdCMV-lacZ, b-galactosidase activity (blue staining) was observed in endothelial cells (black arrowheads) and in rare cells located 
within the adventitia. (C and D) In uninjured arteries infected with the AdSM22-lacZ virus, b-galactosidase activity was observed in rare SMCs 
located within the superficial (abluminal) layer of the tunica media. No staining of endothelial cells was observed. (E and F) After anesthesia 
and intubation, the left and right carotid arteries of Sprague-Dawley rats were isolated and injured by dilatation with a Fogarty catheter. A 24-
gauge intravenous catheter was introduced into the lumen of each isolated arterial segment and 109 PFU of AdSM22-lacZ was instilled for 5 min. 
b-galactosidase activity was observed in the SMCs located within the superficial and deep layers of the tunica media (black arrowheads) and 
within rare cells located within the neointima (open arrowhead). Photomicroscopy was performed using a Zeiss Axiophot microscope. Original 
magnification, A, C, and E, 310; B, D, and F, 340.
Figure 5. Expression of the lacZ transgene after intravenous administration of AdSM22-lacZ. Adult Sprague-Dawley rats received intravenous 
injections of 1010 PFU of AdSM22-lacZ or AdCMV-lacZ. 7 d after infection, the rats were killed and their tissues were fixed and stained for 
b-galactosidase activity. (A, C, and E) Representative histological sections through the liver of control rats (A), AdSM22-lacZ–infected rats (C), 
and AdCMV-lacZ–infected rats (E). b-galactosidase activity was not observed in control livers or the livers of rats receiving intravenous admin-
istration of AdSM22-lacZ virus. In contrast, lacZ expression was demonstrated throughout the livers of rats receiving intravenous injections of 
AdCMV-lacZ. (B, D, and F) Representative histological sections through the lungs of control rats (B), AdSM22-lacZ–infected rats (D), and 
AdCMV-lacZ–infected rats (F). b-galactosidase activity was not bserved in control lungs or the lung  of rats receivi g AdSM22-lacZ. In con-
trast, focal patches of lacZ-expressing cells were observed in the perivascular regions of AdCMV-lacZ–infected rats.
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increased serum concentrations of AP and bilirubin were ob-
served in rats receiving 1010 PFU of the AdCMV-lacZ virus
(P , 0.09). Thus, intravenous administration of high doses of
AdSM22-lacZ did result in mild elevations in liver function
tests. However, the liver function test abnormalities were sig-
nificantly less marked than those observed in rats infected with
identical doses of the AdCMV-lacZ control virus.
Expression of b-galactosidase activity after direct injection
of AdSM22-lacZ into visceral smooth muscle and skeletal mus-
cle. To determine whether the lacZ transgene encoded by
AdSM22-lacZ was expressed in visceral as well as vascular
SMCs, 109 PFU of AdSM22-lacZ was injected directly into the
wall of the rat ureter and bladder, respectively. 7 d after infec-
tion, histological sections from the sites of injection were
stained for b-galactosidase activity. As shown in Fig. 6 A,
dense blue staining was observed throughout the longitudinal
and circumferential layers of SMCs within the wall of the ure-
ter (white arrowheads). In contrast, b-galactosidase activity
was not observed within the epithelial cells lining the lumen of
the ureter (Fig. 6 A, black arrowheads). After direct injection
of AdSM22-lacZ into the bladder mucosa, focal patches of
b-gal1 SMCs were observed surrounding the site of injection
(Fig. 6 B, white arrowheads). In contrast, b-galactosidase activ-
ity was not observed within the bladder epithelium. These data
demonstrated that AdSM22-lacZ programs transgene expres-
sion in visceral as well as vascular SMCs.
The 441-bp murine SM22a promoter is active in embryonic
skeletal muscle cells and the somites of transgenic mice (31).
To determine whether AdSM22-lacZ programs transgene ex-
pression in adult skeletal muscle in vivo, 109 PFU of the
AdSM22-lacZ virus was injected intramuscularly into the rat
rectus abdominus and quadriceps muscles. In contrast to the
dense blue staining observed in visceral SMCs after direct in-
jection into the wall of the ureter and bladder (Fig. 6, A and
B), b-galactosidase activity was not observed in either the rec-
tus abdominus (Fig. 6 C) or quadriceps muscles (Fig. 6 D).
Thus, the lacZ reporter gene encoded by AdSM22-lacZ is ex-
pressed exclusively in visceral and vascular SMCs when ad-
ministered intraarterially, intravenously, or intramuscularly.
Discussion
SMCs subserve diverse functions in organ systems throughout
the body including the modulation of arterial tone, airway re-
sistance, and gut motility. These cells have been implicated in
the pathogenesis of a variety of diseases including atheroscle-
rosis, restenosis after percutaneous transluminal coronary an-
gioplasty, and asthma (1–4). Gene transfer using replication-
defective adenoviral vectors has been used to examine the
pathogenesis of these diseases (40–43) and also holds promise
for their treatment (11). However, adenovirus-mediated gene
transfer is potentially limited in both the clinical setting and in
animal models of human disease, because of the capacity of
these viruses to indiscriminately infect many cell types (5, 15).
In the studies described in this report, we have generated an
RDAd, designated AdSM22-lacZ, which contains the bacterial
lacZ reporter gene under the transcriptional control of the
SMC-specific SM22a promoter (30, 31, 38). We have demon-
strated that AdSM22-lacZ programs SMC-specific expression
of the lacZ reporter gene in cultured cells. In addition, we have
shown that the SMC specificity of the AdSM22-lacZ virus is
maintained in vivo after intraarterial, intramuscular, and intra-
venous administration. Finally, we have demonstrated that
AdSM22-lacZ programs transgene expression in visceral, as
well as vascular SMCs in vivo.
To our knowledge, this report represents the first demon-
stration that the expression of a recombinant gene product en-
coded by an RDAd can be regulated in a cell lineage–
restricted fashion by a transcriptional regulatory element in
normal cells in vivo. Previously, we generated adenoviral vec-
tors containing other cell lineage–specific transcriptional regu-
latory elements and observed that most of these elements lose
their cell lineage specificity when tested in vivo in the context
of an adenoviral vector (Leiden, J., and M. Parmacek, unpub-
lished observation). Similarly, Arbuthnot et al. (44) reported
that RDAd containing transgenes under the transcriptional
control of the alpha-fetoprotein (AFP) promoter are capable
of mediating cell lineage–restricted gene expression in hepa-
toma cells, but not in normal liver parenchyma. It is possible
that the 441-bp murine SM22a promoter may contain an insu-
lator element or a locus control region that is capable of pro-
tecting it from the activity of cryptic transcriptional regulatory
elements located within the adenoviral genome. In this regard
it is noteworthy that the 441-bp murine SM22a promoter is as
active as the most potent viral LTRs in SMCs (30), and func-
tions in an SMC-specific fashion both in vitro and in transgenic
mice in vivo (31, 38, 39).
In transgenic mice the 441-bp SM22a promoter is active in
arterial but not visceral SMCs (29, 31). Therefore, the demon-
stration that the lacZ reporter gene encoded by AdSM22-lacZ
was expressed in visceral as well as vascular SMCs was some-
what surprising. This difference may reflect the fact that in ad-
enovirus-infected cells DNA remains episomal, whereas in
transgenic mice it is integrated into the host genome where its
transcriptional activity can be modulated by alterations in
chromatin structure. In support of this hypothesis, we have ob-
served high-level transcriptional activity of the SM22a pro-
moter in primary cultures of bovine tracheal SMCs after tran-
sient transfection (Solway, J., and M. Parmacek, unpublished
observation). Clearly, caution must be exercised in extrapolat-
ing data generated by either transient transfection analyses or
in transgenic mice to the expected cell lineage specificity of a
transcriptional regulatory element within the context of a rep-
lication-defective adenoviral vector.
RDAd are particularly useful tools for studying the molec-
ular pathogenesis of atherosclerosis and other vascular prolif-
erative disorders. Adenoviruses can be delivered in spatially
and temporally restricted fashions to the vessel wall in both
normal and atherosclerotic vessels in large and small animals
(13, 14). However, previous studies using these vectors to in-
vestigate the pathogenesis of vascular proliferative disorders
have not been able to distinguish effects due to alterations in
Table I. Liver Function in AdSM22-lacZ and
AdCMV-lacZ-infected Rats
ALT AST AP Bilirubin Albumin
Control 6164 9768 229638 0.160.0 2.960.1
1010 SM22-lacZ 104633 137621 306637 0.160.0 3.760.2
1010 CMV-lacZ 153616* 166621* 4426103‡ 0.360.2‡ 3.360.2
Data are expressed as mean6SEM. *P , 0.05 versus control values; ‡P ,
0.09 versus control values.
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vascular SMC gene expression from those resulting from
transgene expression in endothelial or adventitial cells. In this
respect, RDAd-containing transgenes under the control of the
SM22a promoter will allow us to determine directly the effects
of SMC-specific transgene expression on vascular SMC prolif-
eration and neointima formation. In addition, because SM22a
containing RDAd program transgene expression in visceral
SMCs, these viruses may also be useful to examine the patho-
genesis and treatment of diseases mediated by visceral SMCs.
Examples of such diseases include asthma, achalasia, leiomyo-
sarcomas, irritable bowel syndrome, and uterine leiomyomas.
Although the efficacy of RDAd has been established in
both large and small animal models of vascular proliferative
disease (5–7, 12, 21), safety concerns persist due to the capacity
of these viruses to infect most cells and tissues. In this regard,
SM22a promoter-driven adenoviruses may prove advanta-
geous as vehicles to deliver therapeutic genes to the vessel wall
for the treatment of vascular proliferative disorders. The lack
of cytotoxic or cytostatic transgene expression in the endothe-
lial cells at the margins of the arterial injury should, in theory,
promote more rapid reendothelialization of the injured vessel
by facilitating the proliferation and migration of adjacent en-
dothelial cells (5). Of equal importance, the potential for sys-
temic toxicity resulting from ectopic expression of potentially
toxic adenovirus-encoded transgenes in other tissues and or-
gans should be reduced by use of the SMC-specific SM22a
promoter. Finally, recent reports have demonstrated that
much of the immunogenicity of adenovirus-infected cells is
due to cellular and humoral immune responses directed
against foreign transgene proteins (18). By restricting ectopic
expression of adenovirus-encoded transgenes in non-SMC
containing tissues, AdSM22 viruses may also reduce the im-
mune-mediated damage to organs such as the liver and the
lung after intentional or inadvertent systemic administration of
the vector. Our finding of decreased hepatic toxicity after in-
travenous administration of high dose AdSM22-lacZ supports
this hypothesis.
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Figure 6. Expression of the lacZ transgene after direct injection of AdSM22-lacZ into visceral smooth muscle and skeletal muscle. Direct injec-
tion of the AdSM22-lacZ virus into SMC-containing tissues and skeletal muscle was performed after induction of anesthesia and intubation. 109 
PFU of AdSM22-lacZ was injected directly with a 30-gauge needle into the wall of the ureter (A), the bladder wall (B), or intramuscularly (C 
and D). The site of each injection was marked by a suture. 7 d after injection, the sites of injection were isolated, fixed, and stained for b-galac-
tosidase activity. (A) Representative histological section through the ureter injected with AdSM22-lacZ virus. Expression of the lacZ reporter 
gene by AdSM22-lacZ was observed in the circumferential and longitudinal layers of SMCs within the wall of the ureter (white arrowheads). In 
contrast, lacZ expression was not observed in the epithelial cells lining the lumen of the ureter (black arrowheads). (B) Representative histolog-
ical section though the bladder injected with AdSM22-lacZ. lacZ expression (white arrowheads) was observed within SMCs in the bladder wall. 
lacZ expression was not observed in the underlying bladder epithelium. (C and D) Representative histological sections though the rectus ab-
dominus (C) and quadriceps (D) muscles injected intramuscularly with AdSM22-lacZ. In contrast to the b-galactosidase activity observed within 
visceral SMCs (A and B), blue-stained skeletal muscle cells were not observed at the sites of intramuscular injection.
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